Skip to ContentSkip to Navigation
About us Latest news News News articles

Alphavirus-based therapeutic immunization against cervical neoplasia: unraveling immunological mechanisms

02 November 2011

PhD ceremony: Mr. M. Walczak, 14.30 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Dissertation: Alphavirus-based therapeutic immunization against cervical neoplasia: unraveling immunological mechanisms

Promotor(s): prof. C.A.H.H. Daemen, prof. H.W. Nijman, prof. J.C. Wilschut

Faculty: Medical Sciences

Cervical cancer is caused by persistent infection with high-risk human papillomavirus (HPV). Prophylactic HPV-vaccination can prevent cervical cancer. Since available prophylactic HPV-vaccines cannot clear existing HPV-infections and commonly used methods to treat cervical cancer have reached the ceiling of their efficacy and may induce severe side effects, it is of great interest to develop novel therapeutic strategies to treat cervical cancer patients. One of these strategies may be immunotherapy as it is known that cellular immunity plays an important role in clearing HPV infection. Recombinant Semliki Forest virus replicon particles encoding a fusion protein of E6 and E7 from HPV type 16 (SFVeE6,7) represent a promising potential candidate for the therapeutic immunization against HPV-induced cervical cancer. In this thesis, tumor-specific immune responses induced by rSFV replicon particles were investigated and selected immunological mechanisms that influence these responses were elucidated. These immune responses were not (or only marginally) hampered by vector-specific immunity and regulatory T cells and could not be further improved using heterologous prime-boost immunization protocols. On the other hand, local tumor irradiation stimulated specific T cell trafficking (induced by rSFV immunization) into the tumor. Taken together, these pre-clinical studies indicate that rSFV replicon particles induce potent T cell immunity. Therefore therapeutic immunization based on the use of rSFV appears to be a promising and feasible approach to treat HPV-induced neoplasia. Clinical trials are required to prove the efficacy of rSFV in humans.

Last modified:13 March 2020 01.11 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 06 June 2025

    India-Netherlands Hydrogen Valley Fellowship Programme announced

    To coincide with World Environment Day, 5 June 2025, the Indian Department of Science and Technology and the University of Groningen yesterday announced a Hydrogen Valley Fellowship Programme Partnership, allowing talented Indian scholars working on...

  • 28 May 2025

    Gaan avondmensen cognitief sneller achteruit dan ochtendmensen?

    Wie ’s avonds opleeft en laat naar bed gaat, heeft een grotere kans op cognitieve achteruitgang dan een ochtendmens, blijkt uit UMCG-onderzoek.

  • 27 May 2025

    An adventure in the brain

    In the exhibition Brainstorm in the University Mueseum, Iris Sommer and two other brain researchers from Groningen explain the gut-brain connection, how it was discovered that the brain does what it does, and how games motivate you to perform...